Title | VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling. |
Publication Type | Journal Article |
Year of Publication | 2008 |
Authors | Swendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, Hooper A, Rafii S, Blobel CP |
Journal | Circ Res |
Volume | 103 |
Issue | 9 |
Pagination | 916-8 |
Date Published | 2008 Oct 24 |
ISSN | 1524-4571 |
Keywords | ADAM Proteins, ADAM10 Protein, ADAM17 Protein, Amyloid Precursor Protein Secretases, Animals, Chlorocebus aethiops, COS Cells, Endothelial Cells, Extracellular Signal-Regulated MAP Kinases, Fibroblasts, Humans, Membrane Proteins, Mice, Mice, Knockout, Neuropilin-1, Recombinant Fusion Proteins, Signal Transduction, Swine, Time Factors, Transfection, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2 |
Abstract | <p>Vascular endothelial growth factor (VEGF)-A and the VEGF receptors are critical for regulating angiogenesis during development and homeostasis and in pathological conditions, such as cancer and proliferative retinopathies. Most effects of VEGF-A are mediated by the VEGFR2 and its coreceptor, neuropilin (NRP)-1. Here, we show that VEGFR2 is shed from cells by the metalloprotease disintegrin ADAM17, whereas NRP-1 is released by ADAM10. VEGF-A enhances VEGFR2 shedding by ADAM17 but not shedding of NRP-1 by ADAM10. VEGF-A activates ADAM17 via the extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase pathways, thereby also triggering shedding of other ADAM17 substrates, including tumor necrosis factor alpha, transforming growth factor alpha, heparin-binding epidermal growth factor-like growth factor, and Tie-2. Interestingly, an ADAM17-selective inhibitor shortens the duration of VEGF-A-stimulated ERK phosphorylation in human umbilical vein endothelial cells, providing evidence for an ADAM17-dependent crosstalk between the VEGFR2 and ERK signaling. Targeting the sheddases of VEGFR2 or NRP-1 might offer new opportunities to modulate VEGF-A signaling, an already-established target for treatment of pathological neovascularization.</p> |
DOI | 10.1161/CIRCRESAHA.108.184416 |
Alternate Journal | Circ Res |
PubMed ID | 18818406 |
PubMed Central ID | PMC2574836 |
Grant List | / HHMI / Howard Hughes Medical Institute / United States R01 EY015719 / EY / NEI NIH HHS / United States R01 EY015719-06 / EY / NEI NIH HHS / United States |